Published online April 1, 2005
PEDIATRICS Vol. 115 No. 4 April 2005, pp. 1030-1038 (doi:10.1542/peds.2004-2231)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (37)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sinha, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sinha, S. K.
Related Collections
Right arrow Premature & Newborn

A Multicenter, Randomized, Controlled Trial of Lucinactant Versus Poractant Alfa Among Very Premature Infants at High Risk for Respiratory Distress Syndrome

Sunil K. Sinha, MD, PhD*, Thierry Lacaze-Masmonteil, MD, PhD{ddagger}, Adolf Valls i Soler, MD§, Thomas E. Wiswell, MD||, Janusz Gadzinowski, MD, PhD, Julia Hajdu, MD#, Graham Bernstein, MD**, Manuel Sanchez-Luna, MD{ddagger}{ddagger}, Robert Segal, MD§§, Christopher J. Schaber, PhD§§, Joseph Massaro, PhD||||, Ralph d'Agostino, PhD|||| for the Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group

* James Cook University Hospital, Middlesbrough, United Kingdom
{ddagger} Hospital Antoine-Beclere, AP/HP, Paris, France
§ Hospital de Cruces, University of Basque Country, Barakaldo, Bilbao (Bizkaia), Spain
|| State University of New York, Stony Brook, New York
Poznan University of Medical Sciences, Poznan, Poland, and Polish Mother's Memorial Hospital Research Institute, Lódz, Poland
# Semmelweis Egyetem, Budapest, Hungary
** Sharp Mary Birch Hospital for Women, San Diego, California
{ddagger}{ddagger} Hospital General Gregorio Marañon, Madrid, Spain
§§ Discovery Laboratories, Inc, Doylestown, Pennsylvania
|||| Boston University, Boston, Massachusetts

Background. Available therapeutic surfactants are either animal-derived or non–protein-containing synthetic products. Animal-derived surfactants contain variable amounts of surfactant apoproteins, whereas the older-generation synthetic products contain only phospholipids and lack surfactant proteins (SPs). Both decrease morbidity and mortality rates associated with respiratory distress syndrome (RDS) among preterm infants, compared with placebo. However, excess mortality rates have been observed with non–protein-containing synthetic surfactants, compared with the animal-derived products. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved with the addition of peptides that are functional analogs of SPs. Lucinactant is a new synthetic peptide-containing surfactant that contains sinapultide, a novel, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human SP-B. It is completely devoid of animal-derived components.

Objective. We hypothesized that the outcomes for premature infants treated with lucinactant and poractant alfa would be similar. Therefore, we compared lucinactant (Surfaxin; Discovery Laboratories, Doylestown, PA) with porcine-derived, poractant alfa (Curosurf; Chiesi Farmaceutici, Parma, Italy) in a trial to test for noninferiority.

Methods. A total of 252 infants born between 24 and 28 weeks of completed gestation, with birth weights between 600 and 1250 g, were assigned randomly in a multicenter, multinational, noninferiority, randomized, controlled study to receive either lucinactant (n = 124) or poractant alfa (n = 128) within 30 minutes of life. The primary outcome was the incidence of being alive without bronchopulmonary dysplasia (BPD) through 28 days of age. Key secondary outcomes included death at day 28 and 36 weeks postmenstrual age (PMA), air leaks, neuroimaging abnormalities, and other complications related to either prematurity or RDS. An independent, international, data and safety monitoring committee monitored the trial.

Results. The treatment difference between lucinactant and poractant alfa for survival without BPD through 28 days was 4.75% (95% confidence interval [CI]: –7.3% to 16.8%) in favor of lucinactant, with the lower boundary of the 95% CI for the difference, ie, –7.3%, being greater than the prespecified noninferiority margin of –14.5%. At 28 days, 45 of 119 infants given lucinactant were alive without BPD (37.8%; 95% CI: 29.1–46.5%), compared with 41 of 124 given poractant alfa (33.1%; 95% CI: 24.8–41.3%); at 36 weeks PMA, the rates were 64.7% and 66.9%, respectively. The corresponding mortality rate through day 28 for the lucinactant group was lower than that for the poractant alfa group (11.8% [95% CI: 6.0–17.6%] vs 16.1% [95% CI: 9.7–22.6%]), as was the rate at 36 weeks PMA (16% and 18.5%, respectively). There were no differences in major dosing complications. In addition, no significant differences were observed in the incidences of common complications of prematurity, including intraventricular hemorrhage (grades 3 and 4) and cystic periventricular leukomalacia (lucinactant: 14.3%; poractant alfa: 16.9%).

Conclusions. Lucinactant and poractant alfa were similar in terms of efficacy and safety when used for the prevention and treatment of RDS among preterm infants. The ability to enhance the performance of a synthetic surfactant with the addition of a peptide that mimics the action of SP-B, such as sinapultide, brings potential advantages to exogenous surfactant therapy.

Key Words: surfactant protein-B • lucinactant • poractant alfa • bronchopulmonary dysplasia • respiratory distress syndrome • KL4

Abbreviations: RDS, respiratory distress syndrome • BPD, bronchopulmonary dysplasia • PMA, postmenstrual age • SP, surfactant protein • CI, confidence interval

Accepted Dec 2, 2004.




This article has been cited by other articles:


Home page
 Therapeutic Advances in Respiratory DiseaseHome page
M. K. Lal and S. K. Sinha
Review: Surfactant respiratory therapy using Surfaxin/sinapultide
Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 339 - 344.
[Abstract] [PDF]

Home page
 PediatricsHome page
F. Moya, S. Sinha, and R. B. D'Agostino Sr
Surfactant-Replacement Therapy for Respiratory Distress Syndrome in the Preterm and Term Neonate: Congratulations and Corrections
Pediatrics, June 1, 2008; 121(6): 1290 - 1291.
[Full Text] [PDF]

Home page
 PediatricsHome page
W. A. Engle and A. R. Stark
Surfactant-Replacement Therapy for Respiratory Distress Syndrome in the Preterm and Term Neonate: Congratulations and Corrections: In Reply
Pediatrics, June 1, 2008; 121(6): 1291 - 1292.
[Full Text] [PDF]

Home page
 PediatricsHome page
W. A. Engle and and the Committee on Fetus and Newborn
Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate
Pediatrics, February 1, 2008; 121(2): 419 - 432.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
P. T. Lavin
Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates
Pediatrics, November 1, 2007; 120(5): 1223 - 1224.
[Full Text] [PDF]

Home page
 PediatricsHome page
S. Senn, M. Costantini, and G. Rizzi
Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates
Pediatrics, November 1, 2007; 120(5): 1224 - 1225.
[Full Text] [PDF]

Home page
 PediatricsHome page
F. Moya, S. Sinha, and R. B. D'Agostino Sr
Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates: In Reply
Pediatrics, November 1, 2007; 120(5): 1225 - 1226.
[Full Text] [PDF]

Home page
 PediatricsHome page
F. Moya, S. Sinha, J. Gadzinowski, R. D'Agostino, R. Segal, C. Guardia, J. Mazela, G. Liu, and on behalf of the SELECT and STAR Study Investigato
One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials
Pediatrics, June 1, 2007; 119(6): e1361 - e1370.
[Abstract] [Full Text] [PDF]

Home page
 Biophys. JHome page
A. Saenz, O. Canadas, L. A. Bagatolli, F. Sanchez-Barbero, M. E. Johnson, and C. Casals
Effect of Surfactant Protein A on the Physical Properties and Surface Activity of KL4-Surfactant
Biophys. J., January 15, 2007; 92(2): 482 - 492.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
E. Gastiasoro-Cuesta, F. J. Alvarez-Diaz, C. Rey-Santano, A. Arnaiz-Renedo, B. Loureiro-Gonzalez, and A. Valls-i-Soler
Acute and Sustained Effects of Lucinactant Versus Poractant-{alpha} on Pulmonary Gas Exchange and Mechanics in Premature Lambs With Respiratory Distress Syndrome
Pediatrics, February 1, 2006; 117(2): 295 - 303.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
F. R. Moya, S. K. Sinha, and R. D'Agostino
Surfactant Trials
Pediatrics, January 1, 2006; 117(1): 245 - 247.
[Full Text] [PDF]

Home page
 PediatricsHome page
F. R. Moya, J. Gadzinowski, E. Bancalari, V. Salinas, B. Kopelman, A. Bancalari, M. K. Kornacka, T. A. Merritt, R. Segal, C. J. Schaber, et al.
A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants
Pediatrics, April 1, 2005; 115(4): 1018 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. Kattwinkel
Synthetic Surfactants: The Search Goes on
Pediatrics, April 1, 2005; 115(4): 1075 - 1076.
[Full Text] [PDF]